Reliance Life Sciences Private Limited FDA Record

Warning letters, Form 483s, inspections, recalls and 510(k) clearances

  • Latest inspection OAI · Feb 27, 2026
  • Last warning letter 2026
Inspections 8 2 OAI
Recalls 4 0 Class I (0%)
Warning letters 1 Latest Aug 18, 2026
510(k) clearances 0 None on file

Reliance Life Sciences Private Limited has 4 FDA recalls, 8 inspections, 0 510(k) clearances and 1 compliance action on record. FDA has issued 1 warning letter to Reliance Life Sciences Private Limited, the most recent on Aug 18, 2026. FDA has published 1 Form 483 for Reliance Life Sciences Private Limited.

What these totals cover: FDA records filed under the name "Reliance Life Sciences Private Limited".

Latest recall
D-0671-2026 · Class II · Jun 24, 2026
Latest inspection
Feb 27, 2026 · OAI

Summary

Record counts and when each FDA source was last refreshed
RecordsCountLast refreshedSource as ofStatus
Recalls4Nov 11, 2026 (checked Nov 15, 2026, unchanged)File dated Nov 10, 2026Current
510(k) clearances0Nov 15, 2026File dated Nov 9, 2026Current
Inspections8Nov 16, 2026Newest record Nov 5, 2026Current
Compliance actions1Nov 2, 2026Newest record Oct 29, 2026Current

FDA record by year

Reliance Life Sciences Private Limited's FDA inspections, warning letters and recalls in each of the last 10 calendar years (2017 to 2026, 2026 so far).

Reliance Life Sciences Private Limited: FDA inspections per year

2017: 1 inspection (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2018: 2 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2019: 1 inspection (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2020: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2021: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2022: 1 inspection (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2023: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2024: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2025: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2026: 1 inspection (1 OAI), 1 warning letter, 4 recall records (0 Class I)
YearInspectionsOAIWarning lettersRecall recordsClass I
202611140
202500000
202400000
202300000
202210000
202100000
202000000
201910000
201820000
201710000

Inspections are counted by the date they ended, warning letters by the date FDA issued them and recall records by the recall start date. FDA lists one recall record per recalled product, so one recall event can add several.

Reviewing Reliance Life Sciences Private Limited as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Reliance Life Sciences Private Limited yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Reliance Life Sciences Private Limited FDA Warning Letters

1 warning letter on Aug 18, 2026.

IssuedSubjectIssuing officeClose-out letter
Aug 18, 2026 · Letter on fda.gov CGMP/Finished Pharmaceuticals/AdulteratedCenter for Drug Evaluation and Research (CDER)

A warning letter is FDA's formal notice that a company has violated FDA requirements. Each date links to the letter on fda.gov where FDA has it online. Search the text of every letter with the FDA warning letter search.

Reliance Life Sciences Private Limited Form 483s

1 Form 483 published by FDA.

DateDocumentFEI
Feb 27, 2026 · Document on fda.gov 4833009510975

A Form 483 lists the observations FDA investigators made at the end of an inspection. FDA publishes some Form 483s in its reading room, and each date links to that document. Read the observations with the FDA 483 search.

Recent recalls

4 recall records on Jun 24, 2026.

NumberClassProductDate
D-0671-2026Class IIPemetrexed for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For intravenous use only…Jun 24, 2026
D-0673-2026Class IIBortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous…Jun 24, 2026
D-0672-2026Class IIPemetrexed for Injection 500mg/Vial, 1 50 mL Single-Dose Vial per carton, For intravenous use only…Jun 24, 2026
D-0674-2026Class IIAzacitidine for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For Subcutaneous and…Jun 24, 2026

Recent FDA inspections

8 inspections from Aug 23, 2013 to Feb 27, 2026.

DateSiteProductClassificationFEI
Feb 27, 2026Navi Mumbai, IndiaDrugsOfficial Action Indicated (OAI)3009510975
Apr 15, 2022Navi Mumbai, IndiaDrugsNo Action Indicated (NAI)3009510975
Nov 22, 2019Navi Mumbai, IndiaDrugsVoluntary Action Indicated (VAI)3009510975
Oct 16, 2018Navi Mumbai, IndiaDrugsVoluntary Action Indicated (VAI)3009510975
Jan 25, 2018Navi Mumbai, IndiaDrugsNo Action Indicated (NAI)3009510975
Dec 13, 2017Navi Mumbai, IndiaDrugsVoluntary Action Indicated (VAI)3009510975
Aug 14, 2015Navi Mumbai, IndiaDrugsVoluntary Action Indicated (VAI)3009510975
Aug 23, 2013Navi Mumbai, IndiaDrugsOfficial Action Indicated (OAI)3009510975
NAI
No objectionable conditions or practices were found during the inspection.
VAI
Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
OAI
Regulatory and/or administrative actions are recommended.

Look up the inspector observations behind these results with the FDA 483 search, or check for formal enforcement with the FDA warning letter search.

Compliance Actions

FDA's compliance actions data lists 1 compliance action under Reliance Life Sciences Private Limited: warning letters, injunctions and seizures. None came from FDA's Center for Tobacco Products.

Most recent: Warning Letter, Aug 18, 2026.

The warning letters in this data are listed above, together with the letters FDA posts online; a letter found in both is shown once. Other actions are not listed on this page. Search them with the FDA warning letter search or browse all compliance actions.

FDA-inspected facilities

1 inspected site, newest inspection first.

FacilityLocationInspectionsLatest
FEI 3009510975Navi Mumbai, India8Feb 27, 2026

Reliance Life Sciences Private Limited and the FDA: common questions

Has Reliance Life Sciences Private Limited received an FDA warning letter?

Yes. FDA has issued 1 warning letter to Reliance Life Sciences Private Limited. The most recent is dated Aug 18, 2026, with the subject "CGMP/Finished Pharmaceuticals/Adulterated".

Has Reliance Life Sciences Private Limited received an FDA Form 483?

FDA has published 1 Form 483 for Reliance Life Sciences Private Limited in its reading room, the most recent dated Feb 27, 2026. FDA publishes some Form 483s, not all of them.

When did the FDA last inspect Reliance Life Sciences Private Limited?

The most recent FDA inspection on file ended Feb 27, 2026 at Navi Mumbai, India and was classified OAI. FDA has 8 inspections of Reliance Life Sciences Private Limited on file, 2 of them classified OAI (official action indicated).

Has Reliance Life Sciences Private Limited had an FDA recall?

Yes. Reliance Life Sciences Private Limited has 4 FDA recalls on record. The most recent started Jun 24, 2026.

Need more than this page shows? Ask about Reliance Life Sciences Private Limited in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.

Get a free API key

Prefer a PDF? Request a free supplier snapshot.

Is this your company or a supplier you list? Link to this FDA record from your site with a free button.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.